0000905148-21-000282.txt : 20210311 0000905148-21-000282.hdr.sgml : 20210311 20210311173017 ACCESSION NUMBER: 0000905148-21-000282 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210310 FILED AS OF DATE: 20210311 DATE AS OF CHANGE: 20210311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Korbel Gregory Alan CENTRAL INDEX KEY: 0001789032 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39069 FILM NUMBER: 21734403 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aprea Therapeutics, Inc. CENTRAL INDEX KEY: 0001781983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6095104718 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 4 1 form4.xml X0306 4 2021-03-10 0001781983 Aprea Therapeutics, Inc. APRE 0001789032 Korbel Gregory Alan 535 BOYLSTON STREET BOSTON MA 02116 true Chief Business Officer Common Stock 2021-03-10 4 A 0 15000 0 A 25500 D These shares represent restricted stock units which were granted on March 10, 2021, and which will vest and be settled in common stock as follows: (i) 5,000 shares on September 10, 2021, (ii) 5,000 shares on March 10, 2022 and (iii) 5,000 shares on September 10, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. /s/ Scott M. Coiante, attorney-in-fact 2021-03-11